Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 07:00 ET | Source: AC Immune SA

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small...
October 28, 2025 07:00 ET | Source: AC Immune SA

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia...
July 04, 2025 06:15 ET | Source: PolTREG S.A.

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr....
June 13, 2025 11:47 ET | Source: PolTREG S.A.

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera (https://immuthera.bio/) in Delaware to expand its...
May 14, 2025 10:00 ET | Source: Angelini Ventures

Angelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases

Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio’s lead candidate, THN391, for the treatment of Alzheimer’s Disease (AD) and Diabetic...
February 19, 2025 08:30 ET | Source: Annovis Bio, Inc.

Annovis to Host Patients’ Live Forum on February 27, 2025

MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for...
February 05, 2025 08:00 ET | Source: Annovis Bio, Inc.

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
February 04, 2025 16:31 ET | Source: Annovis Bio, Inc.

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
February 03, 2025 06:22 ET | Source: Annovis Bio, Inc.

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
January 07, 2025 08:00 ET | Source: Annovis Bio, Inc.

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...